PHARMACEUTICAL 2017

Acura Pharmaceuticals INC
Rank 249 of 308



PHARMACEUTICAL 2017

Acura Pharmaceuticals INC
Rank 249 of 308

The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 4.6% points.The greatest weakness of Acura Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 108% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	5,910
Cost of Goods Sold	0
Intangible Assets	1,431
Liabilities, Current	3,487
Liabilities, Non-Current	2,979
Other Assets	0
Other Compr. Net Income	65
Other Expenses	477
Other Liabilities	559
Other Net Income	-831
Other Revenues	4,464
Property and Equipment	867
Research and Development	4,028
Selling, General and Administrative Expense	6,516

Output Variable	Value in 1000 USD
Assets	8,208
Liabilities	7,025
Expenses	11,021
Revenues	4,464
Stockholders Equity	1,183
Net Income	-7,388
Comprehensive Net Income	-7,356
BaseVar	15,807
ECR before LimitedLiability	-63%
Economic Capital Ratio	137%